Ocugen reported strong progress in its clinical development, with advancements in its gene therapy candidates OCU400 and OCU410ST, and secured additional funding to extend its operational runway.

• OCU400 is nearing completion of Phase 3 enrollment, with a Biological Licensing Application (BLA) submission planned for 1H 2026, targeting a significant unmet need in retinitis pigmentosa.
• A registered direct offering generated approximately $20 million, extending the company’s financial runway into mid-2026, with potential for an additional $30 million from warrants.
• Ocugen secured an exclusive licensing agreement for OCU400 in South Korea, with projected potential revenues exceeding $180 million in the first decade post-approval.
• OCU410ST's Phase 2/3 trial enrollment is ahead of schedule, aiming to address multiple genetic mutations associated with Stargardt disease, underscoring the high unmet medical need in this patient population.